patient diagnosed with Rolandic syndrome. Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset
Conditions
Interventions
Intervention 1: Control group: receiving Carbamazepine drug, Carbamazepine tab 200 mg (© Galinus Pharmaceuticals) within daily administration of 15-20 mg/kg maintenance dosage. Intervention 2: Interve
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: children between age 6-12 years old (age of onset of disorder and eligible for the cognitive test) diagnosed with Rolandic syndrome by using vEEG or EEG by a pediatric neurologist or epileptologist having no previous history of using AEDs (Anti-epileptic drugs) having no previous history of neurological and/or psychiatric and/or learning and/or genetical disorder(s) previous to the onset of Rolandic syndrome having no history of using drugs that affect cognitive abilities significantly signing ethical consent with total awareness and voluntary
Exclusion criteria
Exclusion criteria: patients who showed any side effects of Carbamazepine (like skin rash, Steven Johnson) and Levetiracetam (like suicide thoughts, acute behavioral problems due to Levetiracetam usage)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of preventing epilepsy attacks. Timepoint: before the drug usage and 2 weeks, 1 and 3 months after the drug usage. Method of measurement: recording the number of epilepsy attacks viewed by family.;Cognitive test score. Timepoint: before the intervention and 3 months after it. Method of measurement: using WISC 5 TEST. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid Nemati
Shiraz University of Medical Sciences
Outcome results
None listed